ORBITA Study: 60 Second Insights
Published: 03 August 2018
-
Views:
9
-
Likes:
7
-
Views:
9
-
Likes:
7
-
Up Next -
Part 4 | Session 4 Rasha Al-Lamee
-
Part 5 | Session 1 Gregg Stone
-
Part 5 | Session 2 Ajay Kirtane
-
Part 5 | Session 3 Darrel Francis
-
Part 5 | Session 4 Rasha Al-Lamee
-
Part 6 | Session 1 Gregg Stone
-
Part 6 | Session 2 Ajay Kirtane
-
Part 6 | Session 3 Darrel Francis
-
Part 6 | Session 4 Rasha Al-Lamee
-
Part 7 | Session 1 Gregg Stone
-
Part 7 | Session 2 Ajay Kirtane
-
Part 7 | Session 3 Darrel Francis
-
Part 7 | Session 4 Rasha Al-Lamee
-
Part 1 | Session 1 Gregg Stone Gregg W Stone
-
Part 1 | Session 2 Ajay Kirtane Ajay J Kirtane
-
Part 1 | Session 3 Darrel Francis Darrel P Francis
-
Part 1 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
-
Part 2 | Session 1 Gregg Stone Gregg W Stone
-
Part 2 | Session 2 Ajay Kirtane Ajay J Kirtane
-
Part 2 | Session 3 Darrel Francis Darrel P Francis
-
Part 2 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
-
Part 3 | Session 1 Gregg Stone Gregg W Stone
-
Part 3 | Session 2 Ajay Kirtane Ajay J Kirtane
-
Part 3 | Session 3 Darrel Francis Darrel P Francis
-
Part 3 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
-
Part 4 | Session 1 Gregg Stone Gregg W Stone
-
Part 4 | Session 2 Ajay Kirtane Ajay J Kirtane
Overview
A short series of 60-second insight videos on the ORBITA Study. Hear the expert views in under one minute!
More from this programme
Part 1
Can you describe the ORBITA study in your own words?
Part 2
Why do you think that ORBITA failed to show a significant improvement in exercise capacity post PCI?
Part 3
After the results of ORBITA should we stop stenting?
Part 4
What was the biggest weakness of ORBITA?
Part 5
What is the biggest strength of ORBITA?
Part 6
How has ORBITA affected your clinical practice?
Part 7